Public Sector: ARV medicines are well stocked except except TLE formulations, ABC/3TC 600/300mg, LPV/r 200/50mg and ABC/3TC 120/60mg. Stock is available incountry for TLD 90 pack (2.0 MOS) and DTG 50mg (13.6 MOS). Interwarehouse transfer of TLD 90 pack (1.3 MOS) and DTG from JMS to be effected in August 2020. Transition of women of reproductive age to TLD should be expedited to preserve stocks of TLE for those intolerant to/ineligible for TLD. Shipments of ABC/3TC 600/300mg (1.7 MOS) and ABC/3TC 120/60mg (4.1 MOS) are expected in September 2020. There has been delayed delivery of Abacavir based formulations due to shortage of API for Abacavir. Consumption of LPV/r 200/50mg is expected to decrease following transition of patients from PI regimens to DTG. Consumption of pediatric LPV/r formulations is expected to increase due to pediatric regimen optimization. PNFP sector: JMS is well stocked on ARVs (>3 MOS) except ABC/3TC 600/300mg and AZT/3TC 30/60mg. Shipments of AZT/3TC 30/60mg (5.5 MOS) and ABC/3TC 600/300mg (6.0 MOS) are expected in August and December 2020 respectively. MAUL is well stocked on ARVs ( > 3 MOS) except for TLD 90 pack, TDF/3TC 300/300mg and Nevirapine syrup. Shipments for Nevirapine syrup (11.6 MOS) and TLD 90 pack (3.2 MOS) are expected in August and September 2020 respectively. Additionally, a shipment of TDF/3TC 300/300mg (9.6 MOS) is expected from the global Fund PNFP gapfill in December 2020.
0 Comments